BofA double downgraded Alcon (ALC) to Underperform from Buy with a price target of $75, down from $100. The firm sees limited share upside and market uncertainty for Alcon, saying 2025 was marked by a market slowdown, competition, and guidance cuts. Consensus expectations are too optimistic heading into 2026, the analyst tells investors in a research note. Bofa believes consensus estimates assume a sharp rebound, share gains, and “ambitious” Unity ramp-up despite Alcon’s low visibility. This leaves little room for positive surprises, the firm contends.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALC:
- Alcon initiated with an Outperform at Oddo BHF
- Staar Surgical shareholder issues letter opposing Alcon merger
- Staar Surgical price target raised to $30.75 from $28 at Wells Fargo
- Staar Surgical price target raised to $30.75 from $28 at Canaccord
- Broadwood continues to urge Staar shareholders to vote against Alcon transaction